A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants - Wikidata - awgldk - TriplyDB

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

http://www.wikidata.org/entity/Q28278852

about

Challenges of drug-resistant malaria Immune mechanisms in malaria: new insights in vaccine development Novel approaches to identify protective malaria vaccine candidates Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection Circumsporozoite protein as a potential target for antimalarials Molecular Farming in Artemisia annua, a Promising Approach to Improve Anti-malarial Drug Production Self-assembling protein nanoparticles in the design of vaccines Application of radiation technology in vaccines development Successful vaccines for naturally occurring protozoal diseases of animals should guide human vaccine research. A review of protozoal vaccines and their designs Malaria in school-age children in Africa: an increasingly important challenge Designing the next generation of medicines for malaria control and eradication Vaccines against malaria Mechanisms of cellular invasion by intracellular parasites Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy In vivo CD8+ T cell dynamics in the liver of Plasmodium yoelii immunized and infected mice Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein Revealing the sequence and resulting cellular morphology of receptor-ligand interactions during Plasmodium falciparum invasion of erythrocytes Interactions of Anopheles gambiae Odorant-binding Proteins with a Human-derived Repellent: IMPLICATIONS FOR THE MODE OF ACTION OF N,N-DIETHYL-3-METHYLBENZAMIDE (DEET)Using mutagenesis and structural biology to map the binding site for the Plasmodium falciparum merozoite protein PfRh4 on the human immune adherence receptor.Proof of principle for epitope-focused vaccine design Young lives lost as B cells falter: what we are learning about antibody responses in malaria.Antimalarial drug discovery - approaches and progress towards new medicines.Identification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite Protein Interrogating the Plasmodium Sporozoite Surface: Identification of Surface-Exposed Proteins and Demonstration of Glycosylation on CSP and TRAP by Mass Spectrometry-Based Proteomics Inhibitor of cysteine proteases is critical for motility and infectivity of Plasmodium sporozoites The March Toward Malaria Vaccines Malaria vaccine based on self-assembling protein nanoparticles Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites Sporozoite immunization of human volunteers under mefloquine prophylaxis is safe, immunogenic and protective: a double-blind randomized controlled clinical trial Factors Associated with Retention to Care in an HIV Clinic in Gabon, Central Africa Production, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic Variation Identification of targets of CD8⁺ T cell responses to malaria liver stages by genome-wide epitope profiling Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of March 2013 meeting Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial Use of vaccines as probes to define disease burden Plasmodium falciparum Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria Elimination in Cambodia.IMPIPS: the immune protection-inducing protein structure concept in the search for steric-electron and topochemical principles for complete fully-protective chemically synthesised vaccine development Diversity of T cell epitopes in Plasmodium falciparum circumsporozoite protein likely due to protein-protein interactions.Control of malaria and other vector-borne protozoan diseases in the tropics: enduring challenges despite considerable progress and achievements.

P2860

Q21032482-1039AC55-FD1B-44FD-924D-E30EAF411BCB Q21032484-18145ECC-2673-4B80-ACA0-982FAF6E361D Q21131082-35209C61-AF8C-421B-B6DE-3B155DC8F9F5 Q24628167-F80049EF-AEAE-448A-8169-F7358B28735A Q26314437-458FC798-2D47-4C3F-B9A1-2647A1167464 Q26752273-14863770-19E0-4509-A7FD-284FBBD0E102 Q26767097-B76420BD-17DF-4CCB-8E94-BF8616836531 Q26798165-C31D2899-5444-468E-92E6-2A4BB2E1B5A3 Q26825650-60FD1BFA-BD42-4FC2-94E0-3FF1E71CB502 Q26858829-C2885061-DDE5-420D-A274-25AB3A67376A Q26859195-BF8BCFCC-1A14-4AED-9CEF-A0BD7EE0D4EA Q26995079-E34E9EDD-36E8-46FC-BFA9-BCEFBB1F0E81 Q27010243-F2F6A2D5-EC51-4582-87FC-FF3E5A0686E1 Q27022146-2AC07F85-A17D-4EB1-BA08-80627592F199 Q27310073-5EDFDEA8-7FB9-4FD0-985C-FA5D4D29672C Q27310086-9B7E9209-D893-4E5F-8AD9-30F985C7960D Q27321307-88C4ABE0-B640-46C3-9C0B-A0C471C2CEF4 Q27675584-9AC3C62B-0747-461B-BA24-6035C05CAC05 Q27680572-A2977DC7-141F-4CC7-80BC-9588FD878C15 Q27681593-54492C90-0674-427C-9710-A050633DD4D0 Q27687235-8DDE3D60-C890-4E89-AB42-861268481A65 Q27693245-A6745855-D57F-4D20-BC9A-5D2430FE902F Q27973488-B7D8FC82-F075-4495-B631-7167E3384615 Q27973871-0145B325-A39D-4F56-AFD9-F2C85AF21E63 Q27974412-307E9CEE-8709-413F-98EE-AE97B2778E57 Q28084325-75152F84-26CA-4B94-BF6D-60DD66380D4B Q28268609-CA83789B-8326-4F4A-B865-5DE9C09BC9A8 Q28486079-A33A6044-81DC-439C-88C9-13D7D4CA9444 Q28541281-805EF152-118D-4A11-811E-4E4576852DCE Q28544964-FD5447F9-37E4-400E-A78E-A59C3915A9C2 Q28550345-44A07E56-BFEE-40EF-8F9E-3BC28714AB19 Q28554439-1CC18044-994B-4994-92FF-180D13AFF8A7 Q28704543-84F25429-C192-41D5-896F-2508A643BDC0 Q29353748-5E93F718-42DE-4AF8-8263-674504A07568 Q29620144-432B33FA-0D71-42C9-8A75-3E4968336AF4 Q30217266-147F31AC-5C3F-4063-AE06-FE36B5E50643 Q30240158-663C041B-1008-42A7-A562-614685694EF3 Q30373743-D2C02BEB-7C7C-4229-AACC-1C9EE927D42D Q30430387-1DA41E7E-3F57-46DE-A894-E70C08DFA547 Q30565638-BDAB8A52-77E7-47D4-A122-D8605AFD9FEA

P2860

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

http://www.wikidata.org/entity/Q28278852

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

@ast

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

@en

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

@nl

type

label

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

@ast

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

@en

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

@nl

prefLabel

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

@ast

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

@en

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

@nl

P1433

Q28278852-355C5B61-1C00-4687-8068-FD5F82DF73F8

P1476

Q28278852-6BE12289-227E-4334-96D2-0B65C7A6D8AB

P2093

Q28278852-03D7E1EF-44E5-43DF-8C50-FD1A47472855

Q28278852-078CA0AF-A91C-44C5-835C-139C9DBD35BF

Q28278852-09F274FC-3E7E-4FDD-A592-03159F6AEF54

Q28278852-0FE6CDB3-87C0-403F-8D97-066BA5530BBA

Q28278852-1331CA58-46B9-4336-B6AC-95B8C49BB8DD

Q28278852-15ADAB1F-AAD6-431E-B394-0C2336F42704

Q28278852-15C9A4F5-4347-404E-8834-6F83ACAC5B56

Q28278852-199FFC77-D99B-4449-A55B-47E7C11BD080

Q28278852-1CA91375-18BE-40A1-9228-CE0723B09FC8

Q28278852-1CC61154-466F-4949-BD85-EAB8DBE2F27C

P304

Q28278852-46AA067A-FF32-4F8B-994A-3133A51AD997

P31

Q28278852-283F12B0-0768-47FF-AB04-E24FFA5EEDD3

P3181

Q28278852-2825F068-7F32-4E34-8576-3B6CD89685F1

P356

Q28278852-171B49FE-B6BD-4AF7-813C-A8E0AA99AD7F

P407

Q28278852-068F1A1A-881F-46BF-BA79-5888F2DC3F81

P433

Q28278852-19FF2C1A-541D-4833-B7F7-C6C8FDDA699A

P478

Q28278852-0AC7E477-5A3F-4415-95AC-F0A7E5D03FEF

P50

Q28278852-046CB871-CE84-4209-8C50-350967AA35B5

Q28278852-0B089436-1A6E-4D5C-BB6B-5EF66B1EAF43

Q28278852-0EBF5CF4-A226-4B29-806D-0767B1457AB7

Q28278852-24F0981A-2C6D-4691-809E-D15C25B22304

Q28278852-25A13A07-9A3C-4CC8-B740-5A640A41FA32

Q28278852-2E338049-27F1-476F-8613-0BD433C94D0D

Q28278852-31ABB13A-3834-4E18-A2CA-4FA558959279

Q28278852-3431BB2F-09C0-4FCE-BEF0-70B510761C57

Q28278852-382A98B3-D4A0-48BE-B68C-636D59045CD6

Q28278852-3A349EBF-CF3D-4E2A-B61A-30393F8F6B7B

P577

Q28278852-DEA33515-A85E-4A5B-9ECE-4EF19394163B

P698

Q28278852-A4E1DDC6-3C8B-49C2-8730-A6CE64248413

P921

Q28278852-3EE082D6-C47B-42F9-BE58-74AE46724154

Q28278852-CC3A0552-EA20-41AC-BFAB-44F5B7433235

P3181

P356

P1433

The New England Journal of Medicine

P1476

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

@en

P2093

Afiya Radford

http://www.w3.org/2001/XMLSchema#string

Alex Agyekum

http://www.w3.org/2001/XMLSchema#string

Ali Mohammed Ali

http://www.w3.org/2001/XMLSchema#string

Ali Said Hamad

http://www.w3.org/2001/XMLSchema#string

Ali Takadir Mtoro

http://www.w3.org/2001/XMLSchema#string

Allan Otieno

http://www.w3.org/2001/XMLSchema#string

Ally Olotu

http://www.w3.org/2001/XMLSchema#string

Amanda Leach

http://www.w3.org/2001/XMLSchema#string

Anangisye Malabeja

http://www.w3.org/2001/XMLSchema#string

Anima Sarfo

http://www.w3.org/2001/XMLSchema#string

P304

2284-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1321897

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1208394

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

367

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Bosco Ouedraogo

Patricia Njuguna

Pedro L. Alonso

Seth Owusu-Agyei

Selidji Todagbe Agnandji

Kingsley Osei-Kwakye

Barbara Gaelle Nfono Ondo Methogo

P577

2012-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23136909

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial